Floatz logo

Recombinant Vaccinia-Cea/Tricom Vaccine

Breast Cancer

National Cancer Institute (NCI)vaccinePhase 2Dormant
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
30/ 100
Competitive Position
59/ 100

Competitive context

891 Active assets in the Breast Cancer cohort.

Asset / SponsorPhaseRating
Lapatinib
University of New Mexico
Phase 3BBB
Darolutamide
Vandana Abramson
Phase 2BBB
Trastuzumab Duocarmazine
Byondis B.V.
Phase 3BB
ERIBULIN MONOMETHANESULFONATE
Henan Cancer Hospital
Phase 4BB
Palbociclib
Hoffmann-La Roche
Phase 4BB

View all 50 →

Same molecule, other indications

Recombinant Vaccinia-Cea/Tricom Vaccine is also rated in:

metastatic neoplasmDormant
CC
Indicative ·
40 / 100
View asset →
Adult Solid NeoplasmDormant
C
Indicative ·
39 / 100
View asset →
colon carcinomaDormant
C
Indicative ·
37 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →